Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F] SPAL-T-06
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[18F] SPAL-T-06 is a second-generation Positron Emission Tomography (PET) radiopharmaceutical tracer developed by Eisai Co., Ltd. for the detection and quantification of tau protein aggregates in the human brain. Tau pathology, characterized by the formation of neurofibrillary tangles, is a core feature of Alzheimer's disease and other tauopathies, correlating more closely with cognitive decline than amyloid-beta plaques. SPAL-T-06 was designed to offer improved sensitivity and higher selectivity for tau aggregates compared to first-generation tracers, with significantly reduced off-target binding to sites such as monoamine oxidase-B (MAO-B). It serves as a critical biomarker tool in clinical research to facilitate early diagnosis, patient stratification, and the monitoring of therapeutic response in trials for neurodegenerative disease-modifying therapies.
- Other names
- 18F-SPAL-T-06
02
Targets
aggregated α-syn (Alpha-synuclein (α-syn))
Beyond the preview
Go deeper on [18F] SPAL-T-06.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F] SPAL-T-06.